Welcome to our dedicated page for ProSomnus news (Ticker: OSA), a resource for investors and traders seeking the latest updates and insights on ProSomnus stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ProSomnus's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ProSomnus's position in the market.
ProSomnus (NASDAQ: OSA), a leader in precision medical devices for Obstructive Sleep Apnea (OSA), announced participation in two investor conferences in March 2023. The conferences are the 35th Annual Roth Conference from March 12-14 and the 33rd Annual Oppenheimer Healthcare Conference from March 13-15. CEO Len Liptak and other executives will engage in discussions, with a fireside chat scheduled for March 13 at 3:30 pm PT and a presentation on March 14 at 1:40 pm PT, both accessible via live webcasts. ProSomnus is recognized for its FDA-cleared, patient-preferred devices, which effectively treat OSA, impacting over 74 million North Americans.
ProSomnus, Inc. (NASDAQ: OSA) announced the appointment of Brian Dow as Chief Financial Officer, effective March 1, 2023. Dow brings over 28 years of experience in life sciences, having successfully taken three companies public and overseen multiple mergers. His previous role as CFO at Agendia involved raising over $100 million in capital. Dow aims to enhance ProSomnus's growth in the Obstructive Sleep Apnea market, with the company having delivered over 187,500 devices and a growing network of over 4,000 medical providers. ProSomnus focuses on providing patient-preferred oral appliance therapy devices.
ProSomnus, Inc. (NASDAQ: OSA) announced its preliminary results for 2022, forecasting a revenue increase of over 35% year-over-year. The company surpassed 187,500 prescribed devices and is advancing several strategic growth initiatives, including expanding its sales team and relocating its manufacturing facility. ProSomnus also reported successful clinical study enrollments for its Obstructive Sleep Apnea (OSA) treatments. The company began trading on the Nasdaq in December 2022. CEO Len Liptak expressed optimism for the future, focusing on making precision oral devices a preferred treatment globally.
ProSomnus, Inc. (NASDAQ: OSA) announced its data from the First Line Obstructive Sleep Apnea Treatment Study (FLOSAT) will be presented for the first time at the American Thoracic Society (ATS) 2023 International Conference in Washington, D.C., from May 19-24. The study, conducted by The Antwerp University Hospital, compares Precision Oral Appliance Therapy (OAT) with Continuous Positive Airway Pressure (CPAP) therapy for moderate to severe OSA. Professors Olivier Vanderveken and Marijke Dieltjens will present findings on May 21. ProSomnus’s OAT devices are FDA-approved and widely accepted, with over 187,500 units delivered.
ProSomnus, Inc. (NASDAQ: OSA) announces full enrollment in the First Line Obstructive Sleep Apnea Treatment study (FLOSAT), comparing precision oral appliance therapy (OAT) to CPAP. Conducted by Antwerp University Hospital, the study includes 121 patients with moderate to severe OSA. The primary endpoint is evaluating overall effectiveness based on efficacy and nightly compliance. Results are expected in early 2023, potentially contributing to a patient-centric approach in treating OSA.
ProSomnus, Inc. (NASDAQ: OSA) has enrolled the first patient in its Severe Obstructive Sleep Apnea (SOS) study, aimed at evaluating the safety and efficacy of the ProSomnus EVO Sleep and Snore device. This pivotal FDA-reviewed trial seeks to establish the device as the first oral therapy option cleared for severe OSA treatment. Key metrics include the apnea-hypopnea index (AHI) and oxygen desaturation index (ODI), monitored for six months. Successful results could lead to FDA approval and greater adoption of this alternative treatment, potentially benefitting millions with OSA.
ProSomnus, Inc. (NASDAQ: OSA) announces that its ProSomnus EVO® Sleep and Snore Device qualifies for Medicare reimbursement. This device, designed for treating Obstructive Sleep Apnea (OSA), has been coded E0486 by the PDAC Contractor and is aimed at enhancing patient comfort compared to CPAP machines. The device is 32% smaller than alternatives and offers personalized treatment. Additionally, a study revealed 91% patient preference for ProSomnus EVO over previous therapies. This marks a significant step in broadening access to effective OSA treatment.
ProSomnus, Inc. (NASDAQ: OSA) announced a peer-reviewed study in Military Medicine, revealing that 88% of active-duty military patients with Obstructive Sleep Apnea (OSA) experienced successful treatment using Precision Oral Appliance Therapy (OAT). The study recorded a 79.6% reduction in sleep apnea events and improvements in various sleep metrics. This positions ProSomnus as a leading alternative to CPAP therapy, with over 150,000 patients treated, highlighting the device's efficacy and potential for broader military adoption.
ProSomnus has completed its business combination with Lakeshore Acquisition I Corp., moving its common stock to trade on Nasdaq under the symbol OSA starting Dec. 7, 2022. This strategic move aims to fund growth in technology, sales, and manufacturing, enabling a four-fold increase in capacity for Oral Appliance Therapy devices. With a growing market demand for OSA treatments, the company aims to address a significant global market opportunity worth $50 billion. Key leadership appointments have also been made to enhance ProSomnus's competitive position in the industry.